Share on LinkedInShare on LinkedIn

ARTICLE · 28 OCTOBER 2026

“A Large Evidentiary Hole”: Court Grants Janssen Summary Judgment In Kickback Case Over Free Infusion Suite Support

Arnold & Porter
Arnold & Porter
Contributor
Arnold & Porter

Arnold & Porter

With over 1,000 lawyers across 16 offices worldwide, Arnold & Porter is renowned for its...

View firm profile
Explore more from Arnold & Porter

A federal court granted summary judgment to Janssen Biotech in a False Claims Act case alleging that free services for in-office infusion suites constituted illegal kickbacks. The decision turned on the relator's lack of evidence that Janssen provided unlawful remuneration and failed to prove the company acted knowingly and willfully in violating the Anti-Kickback Statute.

United StatesCriminal Law

On September 30, 2026, Judge F. Dennis Saylor IV of the U.S. District Court for the District of Massachusetts granted summary judgment to Janssen Biotech, Inc. (Janssen) in United States ex rel. Long v. Janssen Biotech, Inc., No. 16-12182-FDS. The relator alleged that free services Janssen provided to physician practices for in-office infusion (IOI) suites were illegal kickbacks to boost sales of two infusible biologic therapies, Remicade and Simponi ARIA. The court disagreed for two independent reasons: the relator lacked evidence that Janssen provided unlawful remuneration, and, even if she had, she lacked evidence that Janssen acted knowingly and willfully. As the court put it, there was “a large evidentiary hole at the heart of this case.”

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from